Phase 1b study of galunisertib in combination with gemcitabine in Japanese patients with metastatic or locally advanced pancreatic cancer

被引：0
作者：
Masafumi Ikeda
Hideaki Takahashi
Shunsuke Kondo
Michael Mauritius Fabio Lahn
Ken Ogasawara
Karim A. Benhadji
Hisaki Fujii
Hideki Ueno
机构：
[1] National Cancer Center Hospital East,
[2] National Cancer Center Hospital,undefined
[3] Johns Hopkins Bloomberg School of Public Health,undefined
[4] Eli Lilly and Company,undefined
[5] Eli Lilly Japan K.K.,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2017年 / 79卷
关键词：
Galunisertib; Gemcitabine; Japanese; Pancreatic cancer; Pharmacokinetics; Phase 1b; Safety;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1169 / 1177
页数：8
相关论文
共 162 条
[11]  
Urba S(2013)Phase Ib study evaluating safety and pharmacokinetics (PK) of the oral transforming growth factor-beta (TGF-β) receptor I kinase inhibitor LY2157299 monohydrate (LY) when combined with gemcitabine in patients with advanced cancer J Clin Oncol 31 Abstract 2563-undefined
[12]  
Zeh HJ(2016)A randomized phase II, double-blind study to evaluate the efficacy and safety of galunisertib + gemcitabine (GG) or gemcitabine + placebo (GP) in patients with unresectable pancreatic cancer (PC) Cancer Res 76 Abstract CT068-undefined
[13]  
Katz MHG(2009)New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 228-undefined
[14]  
Sohal DPS(undefined)undefined undefined undefined undefined-undefined
[15]  
Mangu PB(undefined)undefined undefined undefined undefined-undefined
[16]  
Khorana AA(undefined)undefined undefined undefined undefined-undefined
[17]  
Shah MA(undefined)undefined undefined undefined undefined-undefined
[18]  
Philip PA(undefined)undefined undefined undefined undefined-undefined
[19]  
O’Reilly EM(undefined)undefined undefined undefined undefined-undefined
[20]  
Uronis HE(undefined)undefined undefined undefined undefined-undefined
12345678910